In the past week, EDIT stock has gone down by -8.90%, with a monthly decline of -12.13% and a quarterly plunge of -36.54%. The volatility ratio for the week is 5.50%, and the volatility levels for the last 30 days are 6.69% for Editas Medicine Inc The simple moving average for the past 20 days is -7.11% for EDIT’s stock, with a -46.16% simple moving average for the past 200 days.
Is It Worth Investing in Editas Medicine Inc (NASDAQ: EDIT) Right Now?
The 36-month beta value for EDIT is at 1.95. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EDIT is 81.70M, and currently, shorts hold a 22.44% of that float. The average trading volume for EDIT on November 04, 2024 was 1.89M shares.
EDIT) stock’s latest price update
The stock price of Editas Medicine Inc (NASDAQ: EDIT) has surged by 2.06 when compared to previous closing price of 2.91, but the company has seen a -8.90% decline in its stock price over the last five trading sessions. zacks.com reported 2024-11-04 that Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago.
Analysts’ Opinion of EDIT
Many brokerage firms have already submitted their reports for EDIT stocks, with BofA Securities repeating the rating for EDIT by listing it as a “Buy.” The predicted price for EDIT in the upcoming period, according to BofA Securities is $15 based on the research report published on August 08, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see EDIT reach a price target of $7. The rating they have provided for EDIT stocks is “Equal-Weight” according to the report published on May 09th, 2024.
Citigroup gave a rating of “Buy” to EDIT, setting the target price at $11 in the report published on October 24th of the previous year.
EDIT Trading at -13.73% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.59% of loss for the given period.
Volatility was left at 6.69%, however, over the last 30 days, the volatility rate increased by 5.50%, as shares sank -13.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.91% lower at present.
During the last 5 trading sessions, EDIT fell by -14.42%, which changed the moving average for the period of 200-days by -65.51% in comparison to the 20-day moving average, which settled at $3.19. In addition, Editas Medicine Inc saw -70.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EDIT starting from Mei Baisong, who sale 518 shares at the price of $3.42 back on Sep 04 ’24. After this action, Mei Baisong now owns 133,895 shares of Editas Medicine Inc, valued at $1,774 using the latest closing price.
O’Neill Gilmore Neil, the CEO of Editas Medicine Inc, sale 1,555 shares at $3.42 during a trade that took place back on Sep 04 ’24, which means that O’Neill Gilmore Neil is holding 313,724 shares at $5,325 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -3.1 for the present operating margin
- 0.91 for the gross margin
The net margin for Editas Medicine Inc stands at -2.89. The total capital return value is set at -0.67. Equity return is now at value -61.23, with -41.75 for asset returns.
Based on Editas Medicine Inc (EDIT), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -4.25. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -59.92.
Currently, EBITDA for the company is -163.12 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 3.31. The receivables turnover for the company is 274.73for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.85.
Conclusion
In conclusion, Editas Medicine Inc (EDIT) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
